KENGREXAL 50 mg, powder for solution for dilution for solution for injection/for infusion 10 bottles
Active ingredients: CANGRÉLOR, Cangrelor tetrasodium
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for injection or infusion10 bottlesintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KENGREXAL 50 mg, poudre pour solution à diluer pour solution injectable/pour perfusion
- Pharmaceutical form
- poudre pour injection ou pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 10 flacon(s) en verre
- Marketing authorisation holder
- CHIESI FARMACEUTICI
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Apr 2016
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63207425CIP75501192CIP133400955011927Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CANGRÉLOR TÉTRASODIQUEpoudre | 55,6 mg · un flacon | SA |
| CANGRÉLORpoudre | 50 mg · un flacon | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.